DATE: July 18, 2018
TIME: 08:00AM PDT
This webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards predictive and mechanistic biomarker discovery for cancer immunotherapy. Dr. Looney will focus on immunotherapy biomarker applications of the Ion AmpliSeq Immune Repertoire Assay Plus, TCR Beta, which provides coverage of the CDR1, 2 and 3 regions of the rearranged TCRB chain. He will highlight recent data from individuals receiving checkpoint blockade immunotherapy for cancer which suggest that TCRB repertoire sequencing of pre-treatment peripheral blood may be used to identify predictive biomarkers for immune-mediated adverse events and objective clinical response.